NO900121L - Probursin. - Google Patents

Probursin.

Info

Publication number
NO900121L
NO900121L NO90900121A NO900121A NO900121L NO 900121 L NO900121 L NO 900121L NO 90900121 A NO90900121 A NO 90900121A NO 900121 A NO900121 A NO 900121A NO 900121 L NO900121 L NO 900121L
Authority
NO
Norway
Prior art keywords
probursin
recombinantly
multifunctional
isolated
treatment
Prior art date
Application number
NO90900121A
Other languages
English (en)
Norwegian (no)
Other versions
NO900121D0 (no
Inventor
Tapan Audhya
Gideon Goldstein
George Heavner
Original Assignee
Immunobiology Res Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunobiology Res Inst Inc filed Critical Immunobiology Res Inst Inc
Publication of NO900121D0 publication Critical patent/NO900121D0/no
Publication of NO900121L publication Critical patent/NO900121L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO90900121A 1988-05-11 1989-05-08 Probursin. NO900121L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19248288A 1988-05-11 1988-05-11
US07/287,462 US4994554A (en) 1988-05-11 1988-12-20 Probursin
PCT/US1989/001962 WO1989010735A1 (en) 1988-05-11 1989-05-08 Probursin

Publications (2)

Publication Number Publication Date
NO900121D0 NO900121D0 (no) 1990-01-10
NO900121L true NO900121L (no) 1990-01-10

Family

ID=26888111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90900121A NO900121L (no) 1988-05-11 1989-05-08 Probursin.

Country Status (15)

Country Link
US (1) US4994554A (de)
EP (1) EP0342015A3 (de)
JP (1) JPH02504155A (de)
KR (1) KR900701826A (de)
CN (1) CN1037712A (de)
AU (1) AU623148B2 (de)
BR (1) BR8906960A (de)
DK (1) DK6590D0 (de)
FI (1) FI900128L (de)
HU (1) HU202885B (de)
IL (1) IL90228A0 (de)
NO (1) NO900121L (de)
NZ (1) NZ229003A (de)
PT (1) PT90525A (de)
WO (1) WO1989010735A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177405B1 (en) * 1992-07-22 2001-01-23 Kenji Nishioka Cyclic analogs of tuftsin
FR2801848B1 (fr) * 1999-12-01 2003-11-28 Pga Electronic Systeme de gestion des mouvements d'un ou de plusieurs sieges de vehicule

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291022A (en) * 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4190648A (en) * 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4584284A (en) * 1985-01-31 1986-04-22 Ortho Pharmaceutical Corporation Bursopoietin

Also Published As

Publication number Publication date
NO900121D0 (no) 1990-01-10
HUT53913A (en) 1990-12-28
HU893527D0 (en) 1990-11-28
EP0342015A3 (de) 1990-10-10
AU3688989A (en) 1989-11-29
FI900128A0 (fi) 1990-01-10
WO1989010735A1 (en) 1989-11-16
CN1037712A (zh) 1989-12-06
BR8906960A (pt) 1990-11-20
PT90525A (pt) 1989-11-30
DK6590A (da) 1990-01-10
EP0342015A2 (de) 1989-11-15
IL90228A0 (en) 1989-12-15
AU623148B2 (en) 1992-05-07
JPH02504155A (ja) 1990-11-29
US4994554A (en) 1991-02-19
KR900701826A (ko) 1990-12-04
DK6590D0 (da) 1990-01-10
FI900128A7 (fi) 1990-01-10
NZ229003A (en) 1992-01-29
HU202885B (en) 1991-04-29
FI900128L (fi) 1990-01-10

Similar Documents

Publication Publication Date Title
NO880929L (no) Produksjon og bruk av il-6.
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
FI883936A7 (fi) Sokeritaudin hoito, hoidossa käyttökelpoiset valmisteet ja niiden valmistus
AU2914889A (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
AU5048090A (en) Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasm in human body, and the cloning of full length cdna thereof
NO893088D0 (no) Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser.
ZA871528B (en) The treatment of diseases of the immune system with diphenylhydantoin and its derivatives
NO883834D0 (no) Fremgangsmaate for fremstilling av nye hiv-proteiner og peptider.
DE69329652D1 (de) Auswirkungen von aktinfilamenten auf die struktur und lyse von fribringerinnseln
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
AU1086888A (en) Primary biliary cirrhosis autoantigen
FI924475A7 (fi) Trinitrobentseenien tai karmiinihapon käyttö syövän ja virusperäisten sairauksien hoidossa
DE3863200D1 (de) In der krebstherapie verwendbare zusammensetzung auf der basis von aminosaeure und vitaminen.
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
NO881502D0 (no) Rekombinante htlv-111 proteiner og anvendelse av disse.
DE68928061D1 (de) Expression von proteinsüssmitteln in hefe
ATE92333T1 (de) Arzneimittel zur intralesionsbehandlung von schuppenartigem zellkarzinomen mit rekombinantem human-alpha-interferon.
NO894042L (no) Gjenkjennelse og behandling av boelgeformer.
EP0342015A3 (de) Peptide, deren Benutzung und sie enthaltende pharmazeutische Zusammensetzungen
DK692087A (da) Peptid med renin-inhibitorisk virkning
EP0278715A3 (de) Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen
AP8500009A0 (en) New phenoxypropanolamine salts and pharmaceutical preparations thereof.
ATE84543T1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.